Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 356

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 356
---
2024, the tax loss carryforwards of BioLineRx Ltd. were approximately $343million. The tax loss carryforwards have no expiration date.
Tax assessments
In accordance with Israeli tax regulations, the tax returns filed by BioLineRx Ltd. through the 2020 tax year are considered final.
Theoretical taxes
The Company has not recognized any deferred tax assets in the financial statements, as it does not expect to generate taxable income in the foreseeable future. The reported tax on the Company’s income before taxes differs from the theoretical amount that would arise using the weighted average tax rate applicable to income of the consolidated entities as follows:
Year ended December 31,
Year ended December 31,
2022
2022
in USD in USD in USD
thousands thousands thousands
thousands thousands thousands
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Loss before taxes ( 24,951 ( 60,614 ( 9,221
Theoretical tax benefit ( 5,739 ( 13,941 ( 2,121
Disallowed deductions (tax exempt income):
Loss (gain) on adjustment of warrants to fair value ( 1,478 2,542 ( 4,056
Share-based compensation 516 534 261
Impairment of intangible asset - 1,542 232
Other 11 11 11
Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created 6,690 9,312 5,673
Taxes on income for the reported year - - -

NOTE 14 - LOSS PER SHARE

The following table contains the data used in the computation of the basic loss per share:

                                                  Year ended December 31,                                                                     
                                                  2022                                                                                        
                                                  2022                                                                                        
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                  in USD thousands                                                                            
  Loss attributed to ordinary shares                                           ( 24,951      )       ( 60,614      )       ( 9,221        )   
                                                  in thousands                                                                                
  Number of shares used in basic calculation                                   773,957               963,366               1,198,108          
                                                  in USD                                                                                      
  Basic and diluted loss per ordinary share                                    ( 0.03        )       ( 0.06